The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...

The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin. This decision marks the first approval of an oral carbapenem ...

Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...